RBCx features AmacaThera’s journey
RBCx, the tech banking and investment arm of the Royal Bank of Canada, has featured AmacaThera’s drug development platform and start-up journey.
Read more
AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain
AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management. Read more
AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care
AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round.Read more
New study setting the stage for non-opioid analgesic in post-surgical pain management
AmacaThera collaborates with University Health Network to evaluate the economic impact of post-surgical opioid use. They are developing non-opioid analgesic, AMT-143, aiming to reduce the reliance on opioid medications.Read more
AmacaThera Doses First Subjects in Phase 1 Clinical Trial for AmacaGel™ Therapeutic Platform
AmacaThera Inc today announced that the first subjects have been dosed in the company's Phase 1 first-in-human clinical investigation of the safety of AmacaGel™.Read more
AmacaThera’s Lung Cancer Applications Recognized in QuickFire Challenge
AmacaThera has received grant funding from the Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma.Read more
How AMT-143 could reduce the post-surgical need for opioids
In June 2022, we created and published “Meet AmacaThera and learn about our novel hydrogel platform,” a 35-second animation. Watch the animated explainer inside this article.Read more
AmacaThera featured in Innovate Toronto
AmacaThera’s drug development platform is featured in Innovate Toronto, an in-depth look at Toronto’s innovation ecosystem. The online compendium and coffee table book features over 300 start-up success stories, including Kepler, which aims to take the Internet into space, and Altus Assessments, which is using data and tech to bring the human side of healthcare education back into focus.
Read more
AmacaThera animation showcases company’s unique biotechnology
In June 2022, we created and published “Meet AmacaThera and learn about our novel hydrogel platform,” a one-minute animation that outlines its approach to drug development.Read more
AmacaThera CEO Mike Cooke accepted to adMare BioInnovations 2021-22 Executive Institute
adMare BioInnovations is pleased to announce the nine women and nine men from diverse backgrounds and representing a wide range of life science businesses across the country, selected to join this year’s adMare Academy Executive Institute.Read more
AmacaThera named CIX Top 20 Early company
Amacathera Inc. has been named a Canadian Innovation Exchange (CIX)’s Top 20 Early company for 2021.Read more
CBC's Quirks & Quarks features AmacaThera Co-Founder Dr. Molly Shoichet
ICYMI: Thanks to CBC's Quirks and Quarks for re-running this November 2020 interview with our co-founder, Dr. Molly Shoichet.Read more
Out of the lab, into the marketplace
Globe and Mail features AmacaThera’s Series A financingRead more